Hervé Duchesne de Lamotte

About Hervé Duchesne de Lamotte

Hervé Duchesne de Lamotte is a seasoned executive in listed-company governance and in the biotechnology and diagnostics sectors. At Eurobio Scientific, he serves as a Director and Deputy Chief Executive Officer. He had previously been a member of the former Management Board since 2010 and became Group Chief Executive in 2019, with particular responsibility for mergers and acquisitions. His long tenure at Eurobio Scientific reflects deep familiarity with the company’s strategic, financial and industrial priorities. He brings more than 35 years of international finance experience, including roughly 30 years in biotechnology and diagnostics. Before joining Eurobio Scientific, he worked from 1981 to 1989 in project management roles for consulting firms in France and the United States, then moved into senior positions in asset-management companies in Paris. In 1991, he entered the pharmaceutical and biotechnology world as a co-founder of the IDM group, where he served as CFO for ten years across France, Canada and the United States. From 2006 to 2008, he was also General Manager for IDM France in Paris until the company was sold to Takeda in 2009. His background combines corporate finance, strategic development, international management and deal execution. Prior to Eurobio Scientific, he led Cirrus Finance Management, a consultancy focused on business and organizational strategy. He also served on the boards of IDM and France Biotech, underscoring his standing within the French life-sciences ecosystem. He holds an MBA in Finance and a Master of Science from MIT, and his first degree is an engineering diploma in aeronautics from SupAero. That blend of scientific training and financial leadership has been central to his career. At Eurobio Scientific, he has been closely associated with the company’s growth strategy, especially acquisition-led expansion and the strengthening of its international footprint.